This website is intended for U.S. healthcare professionals only.

Full Prescribing Information | Visit Patient Site

ENROLL PATIENTS>

ENROLL PATIENTS: VOWST Voyage™ Patient Support Program

VOWST video library

DR. PAUL
FEUERSTADT

3:23

Donor Myth

3:23

KERRY’s STORY

3:23

VOWST Reels:
Healthcare professional videos

Guidance and experience from real VOWST prescribers

3:23

Dr. Paul Feuerstadt

An expert’s approach to a difficult-to-manage condition.

Watch Dr. Paul Feuerstadt speak about the threat of recurrent C. diff and how VOWST can help.^1,2

Featured Topics

Introduction by Dr. Feuerstadt
The threat of rCDI
The clinical challenge of rCDI
A bimodal approach may be required
Antibiotics followed by VOWST: A 1-2 GUT PUNCH
2-step, at-home oral dosing
VOWST and the new rCDI landscape
References and Important Safety Information

An expert’s approach to a difficult-to-manage condition.

Watch Dr. Paul Feuerstadt speak about the threat of recurrent C. diff and how VOWST can help.^1,2

Featured Topics

Introduction by Dr. Feuerstadt
The threat of rCDI
The clinical challenge of rCDI
A bimodal approach may be required
Antibiotics followed by VOWST: A 1-2 GUT PUNCH
2-step, at-home oral dosing
VOWST and the new rCDI landscape
References and Important Safety Information

3:23

Amy Stewart, Nurse
Practitioner

Gut Busters
video series

Dispelling 5 common myths about VOWST among patients

3:23

DONOR MYTH

3:23

MANUFACTURING MYTH

3:23

LAXATIVE MYTH

3:23

DONOR MYTH

3:23

MANUFACTURING MYTH

3:23

LAXATIVE MYTH

Voices for VOWST:
Patient videos

First-person stories from actual VOWST patients

3:23

KERRY’s Story

3:23

JUNE’s STORY

3:23

JUNE’s STORY

ENROLL YOUR PATIENTS IN
VOWST VOYAGE™

SEE THE CLINICAL DATA

References: 1. U.S. Department of Health and Human Services. Antibiotic resistance threats in the United States: 2019. Accessed November 11, 2025. https://www.cdc.gov/antimicrobial-resistance/media/pdfs/2019-ar-threats-report-508.pdf 2. VOWST [Prescribing Information]. Bridgewater, NJ: Aimmune Therapeutics, Inc. 02/2025.

STUDY DESIGN

ECOSPOR III
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults (≥18 years) with recurrent C. diff ^1-3
Primary Endpoint Recurrence at 8 weeks* Secondary Endpoints Adverse events within 24 weeks Recurrence at 4, 12, 24 weeks*
Recurrence confirmed with C. diff toxin test and ≥3 unformed bowel movements per day over 2 days*
10–21 days of vancomycin (125 mg QID) or fidaxomicin (200 mg BID)

ECOSPOR III efficacy endpoints based on intent-to-treat population.

Data were rounded to the nearest whole number for presentation.

STUDY DESIGN

ECOSPOR IV was an open-label, single arm study of 263 participants with ≥1 C. diff recurrences evaluating the safety of VOWST; the secondary endpoint was efficacy⁵

Limitations: open-label study design yields descriptive results limiting interpretations of efficacy and safety without a comparator

ECOSPOR IV
Multicenter, open-label, single-arm trial in adults (≥18 years) with recurrent C. diff ⁵
Primary Endpoint Adverse events within 24 weeks Secondary Endpoints Recurrence at 4, 8, 12, 24 weeks
Recurrence confirmed with C. diff toxin test or PCR and ≥3 unformed bowel movements per day over 2 days^*
10–42 days of vancomycin or 10–25 days of fidaxomicin

Toxin and PCR testing were utilized to determine initial eligibility. Recurrences while on study were confirmed by toxin testing to ensure study integrity.

^†25 placebo recipients and 4 VOWST recipients discontinued ECOSPOR III and enrolled in ECOSPOR IV after experiencing a C. Diff recurrence within 8 weeks.

Data were rounded to the nearest whole number for presentation.